ClinicalTrials.gg
CompletedNCT00272064Updated Dec 7, 2009

ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.

A Phase 3 interventional study of Insulin glulisine and Insulin glargine in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 1 site in Italy. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-12-07.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 2.

Enrollment
8th of 25
352 · median 281
Started
2005
with 1 other
Phase 3
8 of 26
none open now
Registered
6th of 26
by date
Lead sponsor
19 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2005, is one of 8 in phase 3, and was the 6th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 35 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

  • The primary objective of the present study is to verify the superiority of Telecare program vs. standard SMBG program in terms of mean HbA1c value (- 0,5%) at end-point.
  • The secondary objectives of the study are the assessment of: total daily dose of insulin, changes in glycaemic and lipid profile, frequency of hypoglycaemias, changes in weight, health-related quality of life, cost-effectiveness of Telecare program vs. common ambulatory program; general safety (adverse event profile, other routine laboratory parameters).
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 Diabetes Mellitus
  • Patients treated with combined oral antidiabetic drugs(as fixed combination or simultaneous administration) or with metformin in monotherapy at maximal doses for at least 3 months
  • Patients having > 25 Kg/m2;
  • Patients having a ≥ 7.5 % and ≤ 11 %
  • Female patients must be menopausal, surgically sterile, or using effective measures;
  • Female of must use effective contraceptive measures for at least 1 month prior to the entry into the study and should continue to use the same contraceptive method during the overall study period.

Exclusion criteria

Exclusion criteria:

  • Patients diagnosed with type 1 insulin dependent Diabetes Mellitus;
  • History of two or more severe hypoglycaemic episodes within the past 3 months or history of unawareness hypoglycaemia;
  • Active proliferative diabetic retinopathy, as defined by the application of focal or panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require surgical treatment (including laser photocoagulation);
  • Impaired renal function
  • Impaired liver function
  • History of to insulin or insulin analogues or any of the in the Insulin glulisine and Insulin glargine formulation
  • History of hypersensitivity to metformin;
  • Pregnant or breast-feeding women, or women planning to become pregnant during the study;
  • Failure to use adequate (women of current only);
  • Any major organ system disease such as relevant cardiovascular, gastrointestinal, hepatic, neurological, endocrine, haematological or other major systemic diseases or infective diseases;
  • History of drug or alcohol abuse within the last 2 years or current addiction to substances of abuse;
  • Night shift workers;
  • Receipt of an experimental drug or use of an experimental device within the 30 days prior to study entry;
  • Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study;
  • Treatment or likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol;
  • Any disease or condition including abuse of illicit drugs, prescription medicines or alcohol that in the opinion of the investigator or sponsor may interfere with the completion of the study;
  • Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study procedures;
  • Subject is the investigator or any sub investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol;
  • Previous enrolment in the present study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
352 participants (actual)

Study arms

  • Other
    1

    Telecare system

    Drug: Insulin glulisine · Drug: Insulin glargine · Drug: Metformin

  • Other
    2

    Self Monitoring Blood Glucose (SMBG)system.

    Drug: Insulin glulisine · Drug: Insulin glargine · Drug: Metformin

Interventions

  • individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal \< 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous

  • individualized, once daily, dose to reach mean fasting plasma glucose (FPG) \<= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous

  • 1000 mg b.i.d, since the qualification phase, oral

06

What researchers measure

Primary outcomes

  1. Changes of glycosilated haemoglobin (HbA1c)

    Time frame: At least 12 weeks from baseline (visit 3)

Secondary outcomes

  1. Changes in fasting plasma glucose

    Time frame: At each visit

  2. Changes in plasma insulin levels

    Time frame: At each visit

  3. Change of Self-monitoring of Blood Glucose (SMBG)

    Time frame: for the total study duration

  4. Mean Amplitude Glucose Excursion (MAGE)

    Time frame: for the total study duration

  5. Change in lipid profile

    Time frame: V1 (screening) and V5 (end of treatment)

  6. Body weight - Body Mass Index

    Time frame: V1 (screening), V3 (start of titration), V4 (after 12 weeks of treatment), V5 (end of treatment), V6 (end of follow-up)

  7. Total daily dose of insulins (glargine and glulisine)

    Time frame: At each visit (starting from V2 for glargine and from V3 for glulisine)

  8. Health related Quality of Life

    Time frame: V2 (start of titration), V4 (after 12 weeks of treatment), V5 (end of treatment)

  9. Hypoglycemic episodes

    Time frame: for the total study duration

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Milan, Italy
08

References and documents

Publications

  • Del Prato S, Nicolucci A, Lovagnini-Scher AC, Turco S, Leotta S, Vespasiani G; ELEONOR Study Group. Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. Diabetes Technol Ther. 2012 Feb;14(2):175-82. doi: 10.1089/dia.2011.0163. Epub 2011 Oct 20. PubMed 22013886 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2006
First posted
Jan 4, 2006
Start
Oct 2005
Primary completionActual
May 2008
CompletionActual
May 2008
Last update
Dec 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00272064
Lead sponsor
Sanofi
First posted
Jan 4, 2006
Start date
Oct 2005
Primary completion
May 2008
Completion
May 2008
Last update
Dec 7, 2009

Study contacts

PAIZIS GEORGES, MD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin glulisine

Start the discussion